Technology

The Cern Device

Designed to be a safe, effective prescription device/gel treatment delivering controlled, visible-spectrum microbicidal light for localized management of recurrent yeast and bacterial vaginal infections — intended for use at home, as needed, when needed, based on familiar, recurring symptoms.
  • A reusable, precision-engineered intravaginal light-emitting device
  • A proprietary, natural photosensitizing lubricant that enhances microbicidal activity
  • A prescriptive treatment which is designed for home use
Device and gel depicted are for illustrative purposes only and may not represent the final commercial product.

A precision-engineered,
three-part system.

The Cern treatment combines a reusable light-emitting device, a proprietary photosensitizing gel, and a prescriptive protocol designed for home use.
01 — The Device

Light-Emitting Device

A reusable, precision-engineered intravaginal device that emits controlled, visible-spectrum microbicidal light.

02 — The Gel

Photosensitizing Lubricant

A proprietary, naturally derived photosensitizing lubricant that enhances microbicidal activity and reduces treatment duration.
03 — The Protocol

Designed for Home Use

A prescriptive treatment designed for home use, applied similarly to a tampon, as needed, when needed based familiar symptoms.

Proprietary Gel

The photosensitizing gel that powers the light.

The gel contains a proprietary, naturally derived photosensitizer and functions as a lubricant to facilitate device insertion and improve treatment delivery. It enhances the efficiency of the light-based treatment, helping to reduce required treatment duration.

The gel does not possess independent antimicrobial activity and is not intended to alter or disrupt the vaginal microbiome. The antimicrobial effect is driven by the device’s controlled, low-level, visible-spectrum light at the site of infection.

Dual-Pathogen Focus

One device. Two of the most common
vaginal infections.

The CernDevice™ is being developed to address vulvovaginal candidiasis (yeast) and bacterial vaginosis (BV)—two common conditions that frequently coexist but are typically treated separately with antifungal and antibiotic drugs. Cern’s localized, device-based therapy is uniquely positioned to address both fungal and bacterial pathogens through a single treatment modality, offering a differentiated, non-drug approach for women experiencing yeast and/or bacterial infections, including those that may be recurrent.

Yeast (Candida)

Recurrent vulvovaginal candidiasis,
including drug-resistant Candida strains
conventional antifungals struggle to treat.

Bacterial Vaginosis

Recurrent BV — with broader reproductive- health implications, including increased preterm birth risk.
Mechanism of Action

From dysbiosis to symbiosis.

Cern’s controlled, visible-spectrum light works with the proprietary gel to reduce harmful microbes and help restore a healthy, symbiotic vaginal microbiome.
  • Targeted Microbicidal Light

Controlled visible-spectrum light is applied directly at the site of infection, where it interacts with harmful microbes to initiate a localized antimicrobial effect.

  • ROS Generation & Microbial Disruption

ROS effects susceptible microbes, inhibiting their ability to replicate.

  • Targeted Cell Death. Symbiosis Restored.
Cern’s therapy can be tailored so that harmful pathogens are affected while beneficial Lactobacillus species may be preserved, supporting a balanced vaginal microbiome and long-term vaginal health.

Pathogenic Yeast

(e.g., Candida spp.)

Pathogenic Bacteria

(e.g., Gardnerella spp.)

Beneficial Lactobacillus

(e.g., L. crispatus)

ROS

(Reactive OxygenSpecies)

Why Visible-Spectrum Light Matters

Not All Light Is the Same.

Light-based medical applications span a wide range of wavelengths and wavelength selection is not a minor detail. It determines safety profile, tissue interaction, microbicidal specificity, and clinical suitability.

Cern’s platform uses precisely calibrated visible-spectrum light. Which is neither UV nor near UV. Here is why that matters:

Safety Profile

Visible-Spectrum Blue Light

Cern’s visible-spectrum microbicidal blue light has a well-established mucosal tissue safety profile and avoids the ionizing risks associated with UV wavelengths.
UV Differentiation

Not UV-Based

Cern’s platform avoids UVA, UVB, and UVC wavelengths, which may carry mutagenic risk and are not appropriate for intravaginal therapeutic use.
Mechanism Difference

Distinct from Red-LightTherapy

Near-infrared and red-light therapies operate through photo biomodulation not direct antimicrobial action against vaginal pathogens.
Microbicidal Action

Targeted ROS-Mediated Activity

Cern’s visible-spectrum light interacts with endogenous light-absorbing molecules in pathogens to generate ROS-mediated cell death without thermal tissue damage.

Cern’s visible-spectrum approach is fundamentally different from UV or “near” UV violet/purple and red-light systems by wavelength, mechanism, and intended clinical application.

Resistance Advantage

Evolving drug resistant
microbes

These are significant concerns, and they are exactly what Cern is built to address

Conventional therapies target single biochemical pathways, which pathogens can evolve. Cern’s ROS-mediated mechanism operates differently: it attacks multiple cellular structures simultaneously, overwhelming the cell’s repair systems and eliminating the opportunity for resistance to develop. Preclinical data confirm efficacy against all named drug-resistant strains above.

Drug-resistant vaginal pathogens are a growing and underrecognized clinical problem. Species including Candida glabrata, Candida krusei, and fluconazole-resistant Candida albicans are on the rise — strains that current antifungals cannot reliably treat. The rise of antibiotic and antifungal resistant microbes is one of the most pressing concerns in infectious disease today.

0 %+
in vitro reduction of key yeast and bacterial pathogens including drug-resistant strains — demonstrated in preclinical data.
  • Multi-target oxidative mechanism
  • No single pathway for pathogens to evade
  • Efficacy confirmed against resistant strains
The Microbiome

Dysbiosis to Symbiosis

A healthy vaginal microbiome is a complex ecosystem of naturally occurring yeasts and bacteria that coexist in balance—a state known as symbiosis. When this balance is disrupted, Dysbiosis can occur, allowing certain native or introduced microorganisms to become disproportionately abundant and potentially contribute to infection.

Preclinical in vitro data demonstrate preservation of Lactobacillus crispatus alongside significant pathogen reduction. This selective profile, targeting pathogens while supporting the native flora essential to symbiosis is a differentiated outcome no current drug-based therapy can match.

Clinical Status

In development.
On pathway.

  • Currently under IRB-approved human clinical evaluation
  • Classified as Non-Significant Risk (NSR)
  • Advancing under an anticipated Class II De Novo regulatory pathway
ClinicalTrials.gov